羧基麦芽糖铁及其在缺铁性贫血中的应用进展  

Ferric carboxymaltose and its application in iron deficiency anemia

作　　者：王方海[1,2] 赵维[2] 陈建芳[2] 唐伟方[1] 秦勇[2] 

机构地区：[1]中国药科大学理学院,南京211198 [2]江苏神龙药业有限公司,南京210008

出　　处：《中国新药杂志》2017年第9期1011-1015,共5页Chinese Journal of New Drugs

基　　金：江苏省"创新团队计划"项目(2013-043);江苏省"六大高峰人才"项目(2013-SWYY-009)

摘　　要：缺铁性贫血(iron deficiency anemia,IDA)是目前全球最常见的营养素缺乏疾病之一,其治疗药物主要以铁剂为主,口服铁剂应用较早、价廉方便,但效果不理想。静脉铁剂的出现弥补了口服铁剂吸收差、起效慢和不良反应大的不足。近年来新型静脉铁剂不断出现,羧基麦芽糖铁能够满足临床大剂量快速给药的需求,市场前景广阔,是优点最突出的新型静脉铁剂。文章概括了羧基麦芽糖铁的基本理化信息、合成方法、代谢机制、临床研究、国际销售以及国内注册等情况,对羧基麦芽糖铁在国内的研究开发和推广提供了参考。Iron deficiency anemia （IDA） is the most common nutrient deficiency in the world and mainly treated with chalybeate. Although oral iron was initially used with its inexpensive and easy application, the treatment is not satisfactory at present. Intravenous iron could remedy the weakness of oral iron, like poor absorption, slower effect, adverse reactions and worse compliance. New generations of intravenous iron appear continuously in recent years. Ferric carboxymaltose can meet the clinical requirement of large dose iron with short infusion time, which is the most prominent intravenous iron with bright market prospects. In this paper, we summarized the information of basic physical and chemical properties, synthetic methods, metabolic mechanism, clinical research, international marketing and domestic drug registration of the ferric carboxymaltose, providing a reference for the research and development as well as popularization and promotion of ferric carboxymaltose in China.

关 键 词：羧基麦芽糖铁 静脉铁剂 缺铁性贫血 

分 类 号：R973[医药卫生—药品]